Clinical trials: Solid Cancer
Metastatic Solid Tumors
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations.
- Trial name
- BOREALIS-1 (NCT07021898)
- Testing
- ERAS-4001, ERAS-4001 in combination
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Erasca, Inc.
Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult…
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement
- Trial name
- NCT06777316
- Testing
- CGT4859
- Where
- 13 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Cogent Biosciences, Inc.
Advanced Solid Tumors
A Study of HDM2012 in Patients With Advanced Solid Tumor
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2012 in patients with advanced solid tumors.
- Trial name
- NCT07100249
- Testing
- HDM2012
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Advanced Solid Tumor
Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors
HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.
- Trial name
- NCT05367778
- Testing
- HS-10370
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Cancer
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with…
- Trial name
- NCT05025085
- Testing
- AGEN1777, a PD-1 inhibitor
- Where
- 11 sites in United States
- Volunteers
- 25 people
- Sponsor
- Agenus Inc.
Non Small Cell Lung Cancer
Phase I Combination Ixabepilone + Cisplatin
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the…
- Trial name
- NCT00832117
- Testing
- Ixabepilone, Cisplatin
- Where
- 7 sites in United States, Italy
- Volunteers
- 30 people
- Sponsor
- R-Pharm
Advanced Solid Tumor
Study of SGR-3515 In Participants With Advanced Solid Tumors.
The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.
- Trial name
- NCT06463340
- Testing
- SGR-3515
- Where
- 14 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Schrödinger, Inc.
Advanced Solid Tumors
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally…
- Trial name
- NCT05287399
- Testing
- ASC61 200 mg 1, ASC61 200 mg 2, ASC61 300 mg
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Adult Solid Tumor
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
The purpose of the study is to evaluate safety and tolerability and determine a recommended Phase 2 dose for TRC105 when added to standard dose bevacizumab in patients with advanced solid tumors for which bevacizumab is indicated.
- Trial name
- NCT01332721
- Testing
- TRC105 and Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Leukemia, Lymphoma
Study of @neWorld: A Virtual Community for Children With Cancer
RATIONALE: Using an Internet Web site that enables children with cancer to interact online with classmates, participate in classroom activities, get easy-to-read medical information, and chat with family members, medical staff…
- Conditions
- Leukemia, Lymphoma, Psychosocial Effects of Cancer and Its Treatment, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00070421
- Testing
- complementary or alternative medicine procedure, management of therapy complications, psychosocial assessment and care
- Where
- United States
- Sponsor
- Leap of Faith Technologies
Solid Tumors
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
The purpose of this study is to assess the effect of concomitant ramucirumab (IMC-1121B) on the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic acid and 5-fluorouracil, in participants…
- Trial name
- NCT01634555
- Testing
- Ramucirumab (IMC-1121B), Irinotecan, Folinic acid
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Solid Tumor
A Study of the Safety and Tolerability of the Addition of CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours
The treatment of cancer often involves the use of more than one drug at the same time. In this study, patients are treated with the already marketed drug paclitaxel (administered every 3 weeks by infusion)and with the…
- Trial name
- NCT00737555
- Testing
- CHR-2797
- Where
- 2 sites in Netherlands
- Volunteers
- 23 people
- Sponsor
- Chroma Therapeutics
NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC)
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as OTX015) for further studies in participants with advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast…
- Conditions
- NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC)
- Trial name
- NCT02698176
- Testing
- Birabresib
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors
Study on the Safe Dosage and Therapeutic Effect of the Drug YY2201 Tablets on Patients With Advanced Cancer
The goal of this clinical trial is to assess the safety and tolerability of YY2201 in participants with advanced solid tumors. The main questions it aims to answer are: What medical problems do participants have when taking drug…
- Trial name
- NCT06976931
- Testing
- YY2201
- Volunteers
- 42 people
- Sponsor
- Jiangsu YaYao Biotechnology Co., Ltd.
Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC)
A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation
This is a first-in-human, modular, Phase I/IIa, open-label, multi-centre study to assess the safety, tolerability, PK, and preliminary efficacy of AZD0022 monotherapy in combination with other anti-cancer agents in participants…
- Conditions
- Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
- Trial name
- ALAFOSS-01 (NCT06599502)
- Testing
- AZD0022, Cetuximab
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
A Study of LM-24C5 For Advanced Solid Tumors
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
- Trial name
- NCT06187402
- Testing
- LM-24C5
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- LaNova Medicines Limited
Malignant Neoplasm of Digestive System
A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
This study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2).
- Trial name
- NCT05639153
- Testing
- DR30303
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
- Trial name
- NCT04380753
- Testing
- AMG 510
- Where
- 4 sites in Hong Kong, Taiwan
- Volunteers
- 12 people
- Sponsor
- Amgen
Solid Tumor, Adult
Study of ASTX029 in Subjects With Advanced Solid Tumors
This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to participants with advanced…
- Trial name
- NCT03520075
- Testing
- ASTX029
- Where
- 31 sites in United States, France and 2 more
- Volunteers
- 192 people
- Sponsor
- Taiho Oncology, Inc.
Solid Tumors
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
AC220 will be administered as a once daily oral solution given continuously as 28-day treatment cycles, without food and without any rest periods, as long as there is no evidence of disease progression or unacceptably severe…
- Trial name
- NCT01049893
- Testing
- Compound AC220
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Daiichi Sankyo